Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. 2018

Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
Division of Hematology, National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo 190-0014, Japan.

BACKGROUND Waldenström macroglobulinemia (WM) is a rare, indolent B-cell lymphoma. Clinically, chromosome 6q deletion (6q del) including loss of the B lymphocyte-induced maturation protein 1 gene (BLIMP-1) is reported to be associated with poor prognosis. However, it remains unclear how the underlying biological mechanism contributes to the aggressiveness of WM with 6q del. METHODS Here, we conducted oligonucleotide microarray analysis to clarify the differences in gene expression between WM with and without 6q del. Gene ontology (GO) analysis was performed to identify the main pathways underlying differences in gene expression. Eight bone marrow formalin-fixed paraffin-embedded samples of WM were processed for interphase fluorescence in situ hybridization analysis, and three were shown to have 6q del. RESULTS GO analysis revealed significant terms including "lymphocyte activation" (corrected p value=6.68E-11), which included 31 probes. Moreover, IL21R and JAK3 expression upregulation and activation of the B-cell receptor signaling (BCR) pathway including CD79a, SYK, BLNK, PLCγ2, and CARD11 were detected in WM with 6q del compared with WM without 6q del. CONCLUSIONS The present study suggested that the BCR signaling pathway and IL21R expression are activated in WM with 6q del. Moreover, FOXP1 and CBLB appear to act as positive regulators of the BCR signaling pathway. These findings might be attributed to the aggressiveness of the WM with 6q del expression signature.

UI MeSH Term Description Entries
D008258 Waldenstrom Macroglobulinemia A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity. Lymphoma, Lymphoplasmacytoid,Macroglobulinemia,Familial Waldenstrom's Macroglobulinaemia,Lymphoma, Lymphocytic, Plasmacytoid,Primary Macroglobulinemia,Waldenstrom's Macroglobulinaemia,Waldenstrom's Macroglobulinemia,Familial Waldenstrom Macroglobulinaemia,Familial Waldenstroms Macroglobulinaemia,Lymphomas, Lymphoplasmacytoid,Lymphoplasmacytoid Lymphoma,Lymphoplasmacytoid Lymphomas,Macroglobulinaemia, Familial Waldenstrom's,Macroglobulinaemia, Waldenstrom's,Macroglobulinemia, Primary,Macroglobulinemia, Waldenstrom,Macroglobulinemia, Waldenstrom's,Waldenstrom Macroglobulinaemia,Waldenstrom's Macroglobulinaemia, Familial,Waldenstroms Macroglobulinaemia,Waldenstroms Macroglobulinemia
D008297 Male Males
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002896 Chromosomes, Human, Pair 6 A specific pair GROUP C CHROMSOMES of the human chromosome classification. Chromosome 6
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D020869 Gene Expression Profiling The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell. Gene Expression Analysis,Gene Expression Pattern Analysis,Transcript Expression Analysis,Transcriptome Profiling,Transcriptomics,mRNA Differential Display,Gene Expression Monitoring,Transcriptome Analysis,Analyses, Gene Expression,Analyses, Transcript Expression,Analyses, Transcriptome,Analysis, Gene Expression,Analysis, Transcript Expression,Analysis, Transcriptome,Differential Display, mRNA,Differential Displays, mRNA,Expression Analyses, Gene,Expression Analysis, Gene,Gene Expression Analyses,Gene Expression Monitorings,Gene Expression Profilings,Monitoring, Gene Expression,Monitorings, Gene Expression,Profiling, Gene Expression,Profiling, Transcriptome,Profilings, Gene Expression,Profilings, Transcriptome,Transcript Expression Analyses,Transcriptome Analyses,Transcriptome Profilings,mRNA Differential Displays

Related Publications

Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
January 2007, British journal of haematology,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
September 2006, Cancer genetics and cytogenetics,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
January 2014, BioMed research international,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
November 2022, Haematologica,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
January 2001, Cancer genetics and cytogenetics,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
September 2007, European journal of haematology,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
June 2008, Pediatrics and neonatology,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
September 2005, American journal of clinical pathology,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
August 2023, Hematology/oncology clinics of North America,
Naohiro Sekiguchi, and Junko Nomoto, and Akihisa Nagata, and Masahiro Kiyota, and Ichiro Fukuda, and Kazuaki Yamada, and Naoki Takezako, and Yukio Kobayashi
January 2016, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Copied contents to your clipboard!